Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carbon C 14 lerociclib

An orally bioavailable radioconjugate composed of lerociclib, an orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of lerociclib. Upon administration, carbon C 14 lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. Labeling of lerociclib with the radioactive tracer carbon C 14 allows for the evaluation of lerociclib's pharmacokinetic profile, including its absorption, distribution, metabolism and excretion (ADME).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[14C]GB491
14C-GB491
14C-lerociclib
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search